| Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Jounce Therapeutics, Inc. | Chief Operating Officer | Common Stock | 110K | $204K | $1.85 | Jan 10, 2023 | Direct |
| Astria Therapeutics, Inc. | Director | Stock Option (Right to Buy) | 14.1K | Jun 5, 2024 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
|---|---|---|---|---|---|---|---|
| ATXS | Astria Therapeutics, Inc. | Jun 5, 2024 | 1 | $0 | 4 | Jun 6, 2024 | Director |
| ATXS | Astria Therapeutics, Inc. | Jun 2, 2023 | 1 | $0 | 4 | Jun 6, 2023 | Director |
| JNCE | Jounce Therapeutics, Inc. | Jan 9, 2023 | 2 | -$18.5K | 4 | Jan 11, 2023 | Chief Operating Officer |
| JNCE | Jounce Therapeutics, Inc. | Aug 1, 2022 | 2 | $0 | 4 | Aug 3, 2022 | Chief Operating Officer |
| ATXS | Astria Therapeutics, Inc. | Jun 9, 2022 | 1 | $0 | 4/A | Jun 21, 2022 | Director |
| JNCE | Jounce Therapeutics, Inc. | Feb 1, 2022 | 1 | $0 | 4/A | Mar 17, 2022 | Chief Business Officer |
| JNCE | Jounce Therapeutics, Inc. | Jan 7, 2022 | 2 | -$66.6K | 4 | Jan 11, 2022 | Chief Business Officer |
| ATXS | CATABASIS PHARMACEUTICALS INC | Jun 2, 2021 | 1 | $0 | 4 | Jun 2, 2021 | Director |